Klinische Forschung
Studienliste
Übersicht der aktuellen klinischen Studien nach Fachbereich und Rekrutierungsstatus.
Hämatologie
4 Studien in dieser Übersicht
| Status | Studienname | Studientitel | Studienleitung |
|---|---|---|---|
| Rekrutierung offen | ALLTogether | A Phase III Study to Evaluate Blinatumomab vs. Standard Therapy in Pediatric and Young Adult Patients with Newly Diagnosed B-Cell ALL | Univ.-Prof. Dr. Max Mustermann |
| Laufend | AML-REGISTRY | Prospective Registry of Patients with Acute Myeloid Leukemia – Real World Data | OA Dr. Erika Beispiel |
| In Vorbereitung | CAR-T-001 | A Phase II Study of Autologous CAR-T Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma | Univ.-Prof. Dr. Max Mustermann |
| Geschlossen | MDS-001 | A Phase II Study of Azacitidine Plus Venetoclax in Higher-Risk MDS | OA Dr. Erika Beispiel |
Onkologie
4 Studien in dieser Übersicht
| Status | Studienname | Studientitel | Studienleitung |
|---|---|---|---|
| Rekrutierung offen | MK-3475-048 / KEYNOTE-048 | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Univ.-Prof. Dr. Max Mustermann |
| Laufend | CheckMate 9LA | A Phase III Study of Nivolumab (NIVO) + Ipilimumab (IPI) + Two Cycles of Platinum-Doublet Chemotherapy vs. Chemotherapy in First-Line Metastatic NSCLC | OA Dr. Erika Beispiel |
| Geschlossen | DESTINY-Breast04 | A Phase III Study of Trastuzumab Deruxtecan (T-DXd) vs. Physician's Choice of Chemotherapy in HER2-Low Metastatic Breast Cancer | Univ.-Prof. Dr. Max Mustermann |
| In Vorbereitung | ABC-001 | A Phase II Study of ABC123 in Patients with Advanced Solid Tumors | OA Dr. Erika Beispiel |
Rheumatologie
3 Studien in dieser Übersicht
| Status | Studienname | Studientitel | Studienleitung |
|---|---|---|---|
| Rekrutierung offen | RHEUMA-BIO | A Multicenter Study to Evaluate the Efficacy and Safety of Biosimilar Infliximab in Rheumatoid Arthritis | OA Dr. Erika Beispiel |
| Laufend | LUPUS-PROTECT | A Phase II Study to Evaluate the Efficacy and Safety of Belimumab in Patients with Systemic Lupus Erythematosus | Univ.-Prof. Dr. Max Mustermann |
| Geschlossen | PSA-001 | A Phase III Study of an Oral JAK Inhibitor in Psoriatic Arthritis | OA Dr. Erika Beispiel |